FRG-8701 is a novel histamine H2-receptor antagonist used for the inhibition of gastric acid secretion and the prevention of gastric and duodenal ulcers induced by various agents, including HCl/ethanol, stress, indomethacin, and mepirizole; it demonstrates potent anti-ulcer activity with oral ED50 values ranging from 1.1 to 9.4 mg/kg in different ulcer models.